New drugs could drive celiac disease market to over $550 million by 2023, says analyst

31 October 2014

The launches of Alba/Teva Pharmaceutical Industries’ (NYSE: TEVA) larazotide acetate and Alvine/AbbVie’s (NYSE: ABBV) latiglutenase for treating celiac disease could drive sales in the USA and five major European markets (5EU: Germany, France, Spain, Italy and the UK) to reach approximately $551.1 million by 2023, new research suggests.

According to an analyst with research and consulting firm GlobalData, with larazotide acetate expected to enter the US and 5EU markets in first-quarter 2018 and first-quarter 2019, respectively, followed by latiglutenase in first-quarter 2019 and first-quarter 2020, respectively, there will be new therapy choices for the estimated 600,000 diagnosed patients in these countries, whose current standard of care is to follow a strict gluten-free diet (GFD).

Abhilok Garg, GlobalData’s analyst covering immunology, states that Key Opinion Leaders (KOLs) interviewed by GlobalData from May to September this year suggested that the two drugs are likely to be prescribed to celiac patients in combination, due to their differing but complementary mechanisms of action.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK